Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Curis, Inc.’s (CRIS - Snapshot Report) shares gained 7.7% immediately after fourth quarter results were announced. Overall, shares are up 8.8% since earnings were reported.

Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents and the year-ago loss of 15 cents per share.

Fourth quarter revenues were $1.5 million, up 10.6% from the year-ago quarter. Revenues missed the Zacks Consensus Estimate of $2 million. Fourth quarter revenues primarily consisted of $1.4 million of Erivedge royalty revenues.  

Erivedge, commercialized and developed by Roche (RHHBY - Analyst Report) under a collaboration agreement between Curis and Genentech, is approved for the treatment of advanced basal cell carcinoma (BCC).

Research and development expenses increased 9.4% year over year to $3 million. General and administrative expenses rose 3.2% year over year to $3 million.

2013 Details

Curis reported 2013 loss of 15 cents per share, narrower than the Zacks Consensus Estimate of a loss of 17 cents and the 2012 loss of 21 cents per share.

Full year revenues were $15 million, beating the Zacks Consensus Estimate of $14 million. Revenues in 2012 were $17 million. Revenues fell in 2013 due to a decline in license revenues.

Pipeline Update

In Dec 2013, Curis presented interim data from a phase I study on CUDC-907 in patients with relapsed or refractory lymphoma or multiple myeloma. By mid-2014, Curis expects the completion of the dose escalation phase and determination of a recommended dose for future studies. Curis will commence enrollment in expansion cohorts in the second half of 2014.

In Feb 2014, Curis submitted the response and amended protocol to the Food and Drug Administration (FDA) regarding the partial clinical hold placed on CUDC-427 in Nov 2013. In case the partial clinical hold by the FDA is lifted, Curis expects to re-start enrollment in the monotherapy study and also start a phase Ib/II study in HER-2 negative advanced breast cancer patients. 

Curis currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the pharma sector may consider companies like Forest Laboratories Inc. (FRX - Analyst Report) and Lannett Co., Inc. (LCI - Snapshot Report). Forest Labs carries a Zacks Rank #2 (Buy) while Lannett carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%